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Abstract 
Background: The search for highly effective anti-malarial therapies has gathered pace and recent years have seen a 
number of promising single and combined therapies reach the late stages of development. A key drug development 
challenge is the need for early assessment of the clinical utility of new drug leads as it is often unclear for developers 
whether efforts should be focused on efficacy or metabolic stability/exposure or indeed whether the continuation of 
iterative QSAR (quantitative structure–activity and relationships) cycles of medicinal chemistry and biological testing 
will translate to improved clinical efficacy. Pharmacokinetic and pharmacodynamic (PK/PD)-based measurements 
available from in vitro studies can be used for such clinical predictions. However, these predictions often require 
bespoke mathematical PK/PD modelling expertise and are normally performed after candidate development and, 
therefore, not during the pre-clinical development phase when such decisions need to be made.
Methods: An internet-based tool has been developed using STELLA® software. The tool simulates multiple differ-
ential equations that describe anti-malarial PK/PD relationships where the user can easily input PK/PD parameters. 
The tool utilizes a simple stop-light system to indicate the efficacy of each combination of parameters. This tool, 
called OptiMal-PK, additionally allows for the investigation of the effect of drug combinations with known or custom 
compounds.
Results: The results of simulations obtained from OptiMal-PK were compared to a previously published and validated 
mathematical model on which this tool is based. The tool has also been used to simulate the PK/PD relationship for a 
number of existing anti-malarial drugs in single or combined treatment. Simulations were predictive of the published 
clinical parasitological clearance activities for these existing therapies.
Conclusions: OptiMal-PK is designed to be implemented by medicinal chemists and pharmacologists during the 
pre-clinical anti-malarial drug development phase to explore the impact of different PK/PD parameters upon the pre-
dicted clinical activity of any new compound. It can help investigators to identify which pharmacological features of 
a compound are most important to the clinical performance of a new chemical entity and how partner drugs could 
potentially improve the activity of existing therapies.
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Background
Anti-malarial drug development has entered a new era 
where the community can boast to be in possession 
of thousands of anti-malarial active compounds with 
in  vitro growth inhibition IC50 values in the sub-micro 
molar range [1–3]. The increased activity in anti-malar-
ial drug development within the context of the malaria 
eradication agenda, has resulted in the recommendation 
of a series of target candidate profiles (TCPs) and target 
product profiles (TPPs). The TCPs include; fast-parasite 
clearance drug profiles (TCP-1), long-duration of drug 
action profiles (TCP-2), liver-stage (including hypnozo-
ites) and sexual-stage acting drug profiles (TCP-3), and 
chemoprotection profiles (TCP-4). The ambition is to 
combine drugs with one or more TCP attributes to either 
(i) generate a single exposure radical cure and prophy-
laxis (TPP-1, SERCaP) treatment- or (ii) generate a single 
exposure chemoprotection treatment (TPP-2, SECA) [4].
The challenge for the drug discovery community is 
to prioritize anti-malarial hits and leads for subsequent 
pre-clinical development. Lead optimization studies are 
used to enhance the effectiveness of the most promising 
compounds, however it is not always apparent whether 
a drug’s progress is directly in line with desired TCPs 
or TPPs. For example, despite the availability of in vitro 
ADME data (absorption, disposition, metabolism and 
excretion) or in  vivo DMPK (pharmacokinetics) studies 
are unable to show whether a drug’s less desirable phar-
macokinetic attributes can be counter-balanced by other 
more desirable features such as potency. Slow parasite 
killing kinetics (measured as the parasite reduction ratio, 
PRR) are clearly undesirable but can be overcome if the 
drug has an extensive therapeutic half-life. Similarly, 
a rapid-killing drug can be effective even with a short 
therapeutic half-life. Therefore to be confident of a drug’s 
ultimate clinical performance, extensive in  vivo experi-
mentation or pharmacokinetic–pharmacodynamic (PK/
PD) modelling is required.
The major factors influencing the overall clinical per-
formance of a drug include; (i) the drug’s therapeutic win-
dow describing the maximum dose tolerated by patients 
and the minimum dose required to produce a therapeutic 
effect, (ii) the drug’s PK properties describing its clear-
ance and volume of distribution (ultimately reflected in 
the elimination half-life) and (iii) the drug’s PD proper-
ties, which include intrinsic potency (as determined in 
static growth inhibition assays) and time-dependent kill 
dynamics (in the case of malaria the PRR which is a fixed 
characteristic of the biological target/pathway affected by 
the anti-malarial drug class).
The complexity of interacting factors that affect the 
overall performance of a drug make it a challenge dur-
ing lead optimization and pre-clinical drug development 
to fully understand when appropriate PK/PD optimiza-
tion has been (or can ever be) achieved. Pharmacologi-
cal models have the potential to bridge this knowledge 
gap and provide quantitative predictions of drug perfor-
mance. In silico PK/PD models have historically been 
used to investigate anti-malarial monotherapies [5–10] 
and more recently combination therapies [11–14]. How-
ever, these studies do not offer a platform for non-spe-
cialists to explore the dynamic consequences of different 
pharmacological drug properties in order to support 
decision-making in the discovery process.
Presented here, is a user-friendly, internet-based plat-
form “OptiMal-PK” that provides performance data that 
can support pre-clinical anti-malarial drug development 
initiatives. OptiMal-PK allows the user to input drug PK/
PD parameters and utilizes a simple traffic-light display 
system to indicate the minimum number of days the drug 
should be administered to completely clear parasites 
form a patient. OptiMal-PK also allows for the optional 
addition of a partner drug from either a list of currently 
available drugs or a second user-defined drug. This allows 
the users to investigate how drug combinations could 
help shorten treatment times or alter regimens if needed. 
This tool serves two major purposes (i) to develop a bet-
ter understanding of the complex interaction of anti-
malarial drug PK and PD properties and (ii) to identify 
and quantify the key features of any drug under develop-
ment that drive efficacy and therefore represent a focus 
for improvement in the drug development cycle.
The OptiMal-PK tool is an open access tool available 
online [15] which has been designed to be user friendly. 
Users can easily alter PK and PD values and generate 
instantaneous answers for any combination of PK/PD 
parameters with or without the addition of a partner 
drug. The model design, validation and examples of the 




The software used for the construction of this model 
is STELLA® (Systems Thinking for Education and 
Research) which is a package that allows for the dynamic 
visualization and communication of complex differential 
equation systems [16]. The model itself is hosted on forio.
com, a platform for enabling simulations, data explora-
tion and data analytics.
The model
The model, based on Winter and Hastings [11] as previ-
ously described, connects a PK component describing 
the drug concentration in the systemic circulation over 
time and a PD component defining the effect of the drug 
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concentration at any given time on the total parasite 
count. This allows the user to input the PK/PD param-
eters of their experimental drug and roughly estimate its 
predictive clinical performance in patients.
The PK model within OptiMal-PK assumes the drug is 
given orally, and because it is based on a previous model, 
it also assumes first-order absorption kinetics and distri-
bution into one PK compartment. The model was hence 
only defined by two standard differential equations:
where X1 represents the mass of drug in the gut at time 
t and is at its maximum when a dose is administered. 
X2 is the mass of drug in the blood at any given time, it 
increases as the drug is absorbed from the gut at rate ka 
and decreases as the drug is eliminated at a rate ke. Blood 
concentration levels are used throughout the model 
instead of plasma as the model assumes that drug elimi-
nation is driven by total clearance where protein binding 
does not alter overall exposure.
Setting the dose in the interface will then change the 
value of X1 accordingly to match the required dosage. Ini-
tial value for X2 is set to be 0 by default as this represents 
initial drug amount in blood circulation as can be seen in 
Fig. 1.
The drug concentration (C) at any given time (t) is 
determined by dividing the drug mass in blood (X2) by 
the volume of distribution (Vd).
This relationship can be simplified into terms for the 
apparent elimination half-life and the clearance of the 
drug; these parameters are required as user inputs are 
converted by the program into the micro-parameters as 
follows:
The pharmacodynamic component of the model takes 
into account the parasite multiplication rate per para-
site life cycle (PMR = parasite multiplication rate/48 h), 
the concentration of drug in blood at any specific time, 
the PRR (the maximum Parasite Reduction Ratio occur-


















concentration of the drug required to achieve half of the 
maximal parasite reduction rate and the Hill slope, which 
defines the slope parameter of the drug’s C50. The C50 
value is the concentration required to achieve half the 
maximal PRR which is defined by the user. This value is 
ideally extracted from in vitro PRR studies [20], and if not 
available, the IC50 value derived from traditional static 48 
or 72 h assays can be used as a suitable surrogate in Opti-
Mal-PK [21]. Utilizing the IC50 values from static models 
have resulted in realistic predictions that match clinical 
results obtained from various drugs as previously shown 
[11].
The PD model relates drug concentration C to its effect 
on parasite viability. The concentration and time-depend-
ent killing function f(C) for each drug is described using 
the standard Michaelis–Menten equation, i.e.
where Vmax is the maximal drug-killing rate, n is the slope 
of the dose response curve, and C50 is the concentration 
of drug at which 50 % of the maximal PRR occurs.






Fig. 1 Outline of mathematical equations defining the OptiMal-PK 
model. Schematic visualising differential equations which define the 
pharmacokinetics of a drug where it is absorbed from X1 (Gut) to 
X2 (Blood) at a rate of ka and eliminated at a rate of ke. Drug conc. is 
calculated at every time point as X2/volume of distribution. Parasite 
growth and drug induced death is defined by the dynamics of X3
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The change in the number of parasites P over time t can 
be found with the standard differential equation.
where (a) is the parasite growth rate determined by the 
user-defined parasite multiplication rate (PMR). PMR is 
set by default to ten based on previous evidence [22], but 
could be altered by the user to reflect the different PMR 
values that have been reported in different regions [23].
The model additionally calculates the minimum para-
siticidal concentration (MPC), a term often used to 
describe the minimum concentration needed to achieve a 
net decrease in parasite count over time. MPC is directly 
calculated from the drug concentration (C) that results in 
a net reduction in parasite load (e.g. rate of parasite kill 
(f(C)) > PMR, Eq. 8).
The model’s work-flow follows the schematic shown in 
Fig. 1.
Parameter values for all built in partner drugs sup-
plied in the table (see OptiMal-PK website) were taken 
from the paper on which OptimMal-PK is based [11] 
except for atovaquone where the PK parameters were 
taken from [24], the IC50 data from [20] and the PRR val-
ues obtained from clinical data [25] which matches the 
in vivo PRR of drugs with similar mode of action [26].
Stage specificity within OptiMal-PK. A recent paper by 
Hodel et al. [27] investigated the accuracy of this meth-
odology by modelling drugs with long and short half-
lives, with and without stage specificity. The study found 
stage-specificity was only important for short half-life 
drugs with stage-specific killing (e.g. the artemisinins) 
because, depending on the timing of treatment, parasites 
might be in highly drug-tolerant stages or in much less 
tolerant stages. When modelling drugs with very short 
half-lives and stage-specific killing users should note 
that their results could vary but in all other instances, the 
model was shown to be very robust without the addition 
of stage-specificity.
OptiMal-PK has been designed to be a user-friendly 
tool for non-specialists allowing the potential activity of a 
developing drug or new drug combination to be assessed 
but care should be taken into over-interpretation of any 
results due to the previous complexities that have been 



















OptiMal-PK is an internet-based program that uti-
lizes STELLA® (Systems Thinking for Education and 
Research) software. The user-friendly interface allows 
scientists with limited knowledge of mathematical mod-
elling and/or the PK-PD dynamics of anti-malarial drugs 
to easily assess the predicted clinical performance of any 
anti-malarial drug/drug combination and explore the 
consequence of modifying key pharmacological proper-
ties of the drug.
The software works in two simple steps. First the user 
inputs the parameters describing drug PK, PD and initial 
parasite load with user-friendly dials, shown in Fig.  2a, 
and then runs the simulation by pressing the green “run” 
button (Fig.  2b). The OptiMal-PK simulation calculates 
the minimum treatment time (days) required to clear an 
infection and displays the results using a simple traffic 
light system. A green light indicates an adequate num-
ber of treatment days, i.e. the number of days of treat-
ment is sufficient to achieve a cure (defined as reaching 
a total parasite count of less than one, where the simu-
lation stops and indicates achievement of cure). While a 
red light indicates that the number of days of treatment 
administration is insufficient to achieve a cure.
Results and discussion
Model validation
The OptiMal-PK model was based on a validated mech-
anistic PK/PD model implemented in R [28] and previ-
ously published by Winter and Hastings [11] To validate 
the methodology of the OptiMal-PK model, the drug 
concentration and parasite number for the first 30  days 
post-treatment were simulated using both the OptiMal-
PK and R models. The results of both simulations for the 
seven anti-malarial monotherapies previously calibrated 
and validated in [11] were compared in house and found 
to be largely consistent.
Small differences in the absolute values appear to be the 
result of the methods used by the modelling platforms in 
integrating differential equations. Stella® uses the Euler’s 
method to solve differential equations in 1  h time steps 
while the Winter and Hastings model uses an algebraic 
solution for the differential equations. However, parasite 
levels at the selected time points were consistently within 
±10 % across the two models.
The assumption of a one compartment model has been 
used previously to simulate three widely used anti-malar-
ial drug combinations (artemether–lumefantrine, artesu-
nate–mefloquine and DHA–piperaquine) [11]. However 
it is noted that subsequent pharmacological models 
have shown that using a two- or three-compartment PK 
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model, or allowing for conversion to an active metabo-
lite are more appropriate for some anti-malarials (see for 
example [12, 29]). The purpose of the PK model within 
OptiMal-PK is to inform the development of a drug can-
didate so the assumption of a one-compartment model is 
a reasonable and pragmatic first step.
It is important to note that the model makes a large 
number of other simplifications similar to previous mod-
els. For example, OptiMal-PK does not currently include 
bioavailability, dose dependency, active metabolites 
and intercessional/intersubjective variability which are 
known for many drugs. However, the simple nature of the 
interface will allow the user to probe the effects of these 
variables and assess their effect. For instance, the effect 
of bioavailability can be easily explored by reducing or 
increasing the drug dosage, or by altering the clearance 
values. Active metabolites can be modelled by adding an 
extra drug with parameters that match that of the metab-
olite and whose absorption rate is equal to the conversion 
rate to the metabolite.
For combination therapy simulations, a model of domi-
nant killing was utilised, where the rate of kill is equal to 
that of the drug inferring the fastest kill rate at each time 
point as previously described in [12].
A case study—Is OZ439 sufficiently effective for delivery 
as a one dose therapy and how it could it be improved?
OZ439 is a peroxide anti-malarial drug that has been 
designed to produce a single oral dose cure for malaria 
[30]. Unlike other peroxides, OZ439 showed excellent 
activity in Plasmodium berghei-infected mice produc-
ing a complete cure after a single 30 mg/kg dose admin-
istered orally. The clinical PK data for the drug were 
described in a later publication [31] and showed superior 
PK properties when compared to similar drugs within the 
same class, with an elimination half-life that exceeds 24 h 
due partially to a relatively slow clearance. However, the 
question remains of whether OZ439 could truly deliver 
a single dose cure (defined as the reduction of total num-
ber of parasites to less than one) when administered as a 
Fig. 2 Interface of the OptiMal-PK tool. a Shows the panels where the user could use slide bars and turning knobs to adjust the PK parameters 
(dose, dosing frequency, absorption rate, apparent elimination half-life and clearance/F) and the PD parameters (Drug Potency) such as parasite 
reduction ratio (PRR), IC50, Mwt (to adjust for units of IC50 (moles) and dose (mgs) and the Slope factor (Hill’s Constant). Infection Severity Panel 
where the user could adjust the initial parasite count as well as the parasite multiplication ratio and finally a panel where the user could add an 
extra drug from a list of built-in drugs or a new drug whose parameters could be adjusted by the user. b Shows the output section of the tool, 
where upon running the simulation, the number of days of treatment required to clear parasites at the chosen PK/PD parameters will flash green, 
while the numbers of days that won’t be sufficient will flash red
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single therapy in clinical studies, although it is accepted 
that the drug will be eventually deployed as a combina-
tion. OptiMal-PK was utilised to predict the clinical per-
formance of OZ439 in future human studies. A number 
of simulations were executed assuming different dos-
ages and feeding states and then allowed the program to 
assess the minimum number of days needed to achieve 
total elimination of parasites in the subjects under each 
scenario.
The OptiMalPK model calculated minimum number of 
days needed for treatment using the PK and PD param-
eters that are presented in Table 1 (derived from [30–32]) 
In this example, different doses of OZ439 were compared 
in a capsule and oral dispersion forms on empty (lower 
exposure) or full (higher exposure) stomachs based on 
clinical data. The results demonstrate that a single mono-
therapy dose of 800 or 1200 mg (as a capsule, it is impor-
tant to note that the disposition characteristics of OZ439 
capsules differ significantly from a drug dispersion for-
mulation, see below) would be insufficient for the suc-
cessful elimination of parasites in all patients and would 
result in recrudescence within 9 days after the treatment. 
The model predicts that 1200 mg OZ439 capsule would 
need at least 2  days of treatment to completely cure a 
malaria infection, as defined by depletion of parasite total 
number to one.
However, the simulations show that a single 800  mg 
dose of the oral dispersion formulation in fed or fasted 
subjects would lead to a cure following a single admin-
istration; administering the drug in the capsule form, 
not the oral dispersion formulation, seems to fail a 1 day 
treatment regimen according to the model. Neverthe-
less, even for the superior oral dispersion formulation, 
if metabolism is slightly accelerated (decreasing half-life 
by 20  %) in a proportion of the target population, the 
single dose for the oral dispersion would be rendered 
insufficient in either fed or fasted subjects. These data 
suggest that the single dose regimen is very unforgiv-
ing which could have very serious consequences in field 
deployment in large patient populations if OZ439 were to 
be deployed alone. Additionally a modest two to three-
fold decrease in potency (increase in IC50 from x–y; i.e. 
emergence of moderate resistance) would also make the 
single dose insufficient for an absolute cure (Fig. 3). Opti-
Mal-PK highlights the sensitivity of single dose OZ439 to 
emergence of low level parasite resistance and moderate 
population PK variations. Given the large variability of 
PK parameters shown in Table 1 (30–115 %) the simula-
tions here show that a single dose of OZ439 dispersion 
would leave a significant proportion of subjects at risk of 
incomplete elimination of malaria parasites, treatment 
failures and parasite recrudescence and increased pres-
sure for resistance development.
Case study 2—effect of resistance on drug activity 
and mitigating strategies
Chloroquine (CQ) was for many decades a primary 
chemotherapeutic agent in anti-malarial therapy. Resist-
ance to the 4-aminoquinolines was initially reported in 
Southeast Asia and South America and subsequently 
spread to almost every malaria endemic region in the 
world [33]. CQ was used as an example on how drug 
resistance would affect the outcome of treatment. The 
original chloroquine parameters are all based on those 
previously reported as described earlier [11]. The num-
ber of days it takes to achieve a cure was investigated 
as drug resistance increases (IC50 was elevated in 40  % 
increments, Fig.  4). Using CQ sensitive IC50 values (e.g. 
≤62.7  nM [34]), the model predicts successful outcome 
with a 3-day treatment, consistent with published clinical 
data [35], and consistent with WHO guidelines for CQ 
[36]. When parasite CQ sensitivity values are increased 
Table 1 PK and PD parameters of OZ439 after oral delivery in fasted and fed patients as reported in the literature
Parameter Estimated value Reference
Fasted (capsule) Fed (oral dispersion) Fasted (oral dispersion)
Dose (mg) 800–1200 800 800
Absorption rate (ka) 0.72 0.72 1.5 [31]










Parasite reduction rate (PRR) (/48 h) 3000 3000 3000 Assumed to be similar to artemisinin
IC50 (nM) 4.5 4.5 4.5 [30]
Molecular weight (Da) 469.6 469.6 469.6 [30]
Hill’s slope constant 4 4 4
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to resistant values e.g. generally considered ≥100  nM 
[37, 38], the model predicts a requirement of 4 or more 
days of treatment, depending on the fold increase of CQ 
C50 (Fig.  4), all PK parameters derived from [39] and 
PD parameters from [34]. These data are in agreement 
with clinical trials performed in CQ resistant regions in 
Afghanistan where 60 % of the population failed a 5-day 
treatment of CQ [40].
Parameters that could be altered to reverse the effect of 
increasing the IC50 of CQ were then investigated. Assum-
ing a 4.6-fold increase of IC50 from 62.7 to 288.4 nM the 
drug will not be able to deliver a cure within 14  days, 
altering the dosing regimen from once daily dosing to 
twice daily brings the number of days needed to achieve 
a cure to five to 6 days according to the model, while arti-
ficially increasing the half-life by 40 % would reduce the 
predicted number of days needed to achieve a cure down 
to seven to 8  days. Increasing the PRR by tenfold from 
1000 only improves the activity of CQ slightly accord-
ing to the model. Although these changes are purely an 
academic exercise it highlights the key parameters that 
need to be considered in the discovery process where 
candidate selection could take into account these phar-
macological features. Importantly, even if it were possible 
to achieve radical changes in the drug properties, such as 
increasing its PRR by tenfold or its half-life by 40 %, these 
changes are unable to mitigate resistance resulting from a 
4.6-fold increase in the CQ IC50, emphasizing the need to 
avoid resistance development in the first case by appro-
priate use of forgiving dosage regimens.
Case study 3—studying the potential of long‑duration 
dihydroorotate dehydrogenase (DHODH) inhibitor 
(DSM265) for treatment of malaria
OptiMal-PK is used here to study the therapeutic poten-
tial of a drug, DMS265, with slow elimination kinetics 
and killing dynamics. Potency and clinical PK proper-
ties were used as previously reported [26] and shown in 
Table 2 (PRR value was estimated to be 17 based on data 
shown in [26]).
The simulations show that using the parameters in 
Table  2, at least four doses would be needed to achieve 
complete elimination of parasites in the circulation of 
patients. However, if metabolism is slowed down by 
a factor of only 10–20  % (by increasing half-life from 
130 to 170 h) the drug would be capable of achieving a 
cure in one to two doses. These data, therefore, sug-
gest that in back-up programmes aimed at delivering 
Fig. 3 OptiMal-PK predictions of OZ439 clinical activity. Results of 
OptiMal-PK simulations on OZ439. Assuming a single dose of either 
1200 mg capsule (fasted, green line), oral dispersion in fed subjects 
with (blue) or without (red) an assumption of 20 % reduction in t1/2 or 
a threefold increase in IC50 (purple)
Fig. 4 OptiMal-PK predictions of chloroquine resistance upon its 
activity. Effect of resistance on outcome of chloroquine (CQ) treat-
ment: The graph show the increase in number of days needed to 
achieve a cure with CQ at increasing IC50 values from 62.7 up to 288.4. 
Increasing IC50 values indicate increased resistance to the drug
Table 2 PK and  PD parameters of  DSM265 as  reported 
in the literature
Human PK values are reported from allometric scaling performed by [26]
Parameter Estimated value 
Dose (mg) 200–400 mg
Absorption rate (ka) N/A (assumed to be 1)
Elimination half-life (h) 130 h
Clearance (L/h/kg) 0.003 (allometrically scaled from 
rodents)




Molecular weight (Da) 402
Hill’s slope constant ~1 (extrapolated from graph)
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second-generation DHODH inhibitors, a focus on 
improving the therapeutic half-life of the drug may be 
more rewarding than a focus on potency alone.
Like OZ439, albeit with a completely different mode of 
action and different PK/PD properties, DSM 265 seems to 
be on the cusp of delivering a single dose cure. As with 
OZ439, the laudable aim of achieving a single dose cure, 
needs to take into account inherent parasite and patient 
variability at the population level, as the models suggest 
that these drugs may end up being deployed in very unfor-
giving dosage regimens, setting them up for premature 
failure due to either inadequate clinical performance in 
some patients or the early development of parasite resist-
ance, something that is readily achieved with DSM265 in 
laboratory settings under moderate drug pressure.
Conclusions
OptiMal-PK is an open access, internet-based tool 
designed for the wider anti-malarial drug discovery com-
munity. It allows non-specialists to identify which phar-
macological features of a compound are most important 
to the clinical performance of a new chemical entity or 
new drug combination. OptiMal-PK should therefore 
serve as an aid to critical decision-making during anti-
malarial drug development programmes.
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